The ATG5 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population generated from the human SK-HEP-1 liver adenocarcinoma cell line, carrying disruptive modifications at the ATG5 locus. This polyclonal knockout product provides a heterogeneous pool of cells with targeted ATG5 loss-of-function alterations, enabling robust investigation of autophagy deficiency in a hepatic cancer background without the constraints of clonal selection.
SK-HEP-1 is an epithelial-like cell line originally isolated from the ascites of a patient with liver adenocarcinoma. Widely employed as a hepatocellular carcinoma (HCC) model, it displays metabolic reprogramming, invasive capacity, and drug resistance traits. The cell line maintains active PI3K-AKT-MTOR and AMPK signaling pathways, which are key nodes regulating autophagy initiation and progression, rendering it highly appropriate for studying autophagy-dependent phenotypes in liver cancer.
ATG5 encodes a core autophagy protein indispensable for autophagosome elongation. Through the actions of ATG7 and ATG10, ATG5 is covalently linked to ATG12 and subsequently forms a multimeric complex with ATG16L1. This ATG12?CATG5?CATG16L1 conjugate functions as an E3-like ligase that facilitates the lipidation of MAP1LC3B (LC3) on expanding phagophores. Upstream, nutrient-sensing kinases MTOR and AMPK regulate the ULK1 initiation complex, integrating metabolic cues with autophagic activity. Downstream, ATG5-dependent lipidation generates LC3-II, promoting cargo sequestration, autophagosome closure, and eventual degradation of substrates including the selective autophagy receptor p62/SQSTM1. Thus, ATG5 sits at a pivotal nexus within the autophagy pathway; its knockout abolishes macroautophagy, mitophagy, and xenophagy, severely compromising cellular quality control and stress adaptation.
In the context of hepatocellular carcinoma, ATG5 ablation in SK-HEP-1 cells yields a powerful model to examine autophagy??s role in tumor biology. HCC tumors frequently rely on autophagy to sustain proliferation under nutrient limitation, resist chemotherapeutic insult, and support metastatic spread. Loss of ATG5 disrupts autophagic flux, leading to accumulation of dysfunctional mitochondria and protein aggregates, and can sensitize cells to anticancer drugs. This model permits detailed dissection of autophagy-dependent survival mechanisms, resistance pathways, and the crosstalk between autophagy and the dysregulated PI3K-AKT-MTOR and AMPK signaling networks in liver adenocarcinoma.
Standard experimental readouts include western blotting for LC3-II and p62 in the presence of lysosomal inhibitors (e.g., chloroquine) to measure flux, immunofluorescence visualization of LC3 puncta, and cell viability assays under starvation or pharmacological challenge. The polyclonal nature of the knockout population captures a broad spectrum of genetic variance, facilitating robust phenotypic screening. Further applications encompass metabolic profiling, transwell migration and invasion assays, apoptosis detection, and high-throughput drug sensitivity testing. By eliminating ATG5-dependent autophagy, researchers can validate therapeutic targets and uncover context-specific vulnerabilities. For additional technical documentation or to discuss customized experimental strategies, please contact Ascent Research.
